Estrogen patch benefits: the 15-year trial that studied men, not women

Estrogen patch benefits: the 15-year trial that studied men, not women

Estrogen patch benefits: the 15-year trial that studied men, not women

The largest randomized trial ever run on estradiol patches did not enroll a single woman. It enrolled 1,360 men with locally advanced prostate cancer, recruited them between 2007 and 2022, and published in the New England Journal of Medicine in March 2026. One of its headline findings was that the patch cut hot flashes roughly in half.

Estradiol absorbed through the skin behaves differently from estradiol swallowed as a tablet. Skin delivery sends the hormone directly into the bloodstream. A tablet passes through the liver first, where it alters production of the proteins that control clotting. That difference in route explains most of what separates the two forms on safety, and it is why the patch keeps outperforming the tablet in large observational datasets.

This article explains what the prostate cancer trial found, why the delivery route changes the risk profile, and which questions about estrogen patches in women still have no randomized answer.

Table of contents

Key takeaways

What the evidence shows Why it matters to women
The PATCH and STAMPEDE-1 trial randomized 1,360 men to transdermal estradiol or standard hormone injections, recruiting from 2007 to 2022. It is the largest randomized trial of estradiol patches measured against hard clinical outcomes, and no women were enrolled.
Hot flashes of any severity occurred in 44% of the patch group and 89% of the injection group. The symptom that drives most menopause treatment decisions was measured rigorously, in men, over years.
Three-year metastasis-free survival was 87.1% with patches and 85.9% with injections. Steady estradiol delivered through skin held up against an established treatment on a hard endpoint.
Among 80,396 UK women who had a blood clot, oral hormone therapy carried roughly 70% higher clot risk than transdermal. Route of delivery, not the hormone itself, drives much of the clotting risk women were warned about.
Transdermal therapy in that same analysis showed no increase in clot risk, with an odds ratio of 0.93 (95% CI 0.87 to 1.01). The researchers concluded transdermal treatment is underused, with oral preparations still overwhelmingly preferred.
8.8% of NIH grant spending from 2013 to 2023 went to women's health research. Menopause was not tracked as its own NIH funding category until 2024.


What a prostate cancer trial revealed about estradiol patches

Prostate cancer grows in response to testosterone, so standard treatment shuts testosterone down. The usual method is an injection of an LHRH agonist every four or twelve weeks. It works, and it produces a familiar list of consequences: hot flashes, joint pain, bone thinning, low libido, and cognitive complaints. Any woman who has read a menopause symptom list will recognize the pattern, because the underlying state is the same. Sex hormones fall, and the body reacts.

British researchers led by Ruth Langley at the MRC Clinical Trials Unit at University College London asked whether an estradiol patch could suppress testosterone as effectively while sparing men the worst of those effects. The trial, known as PATCH and run alongside STAMPEDE-1, randomized 1,360 men. Seven hundred twenty-one received patches delivering 100 micrograms of estradiol every 24 hours, starting at four patches twice weekly. Six hundred thirty-nine received the standard injections. Recruitment ran for fifteen years. Funding came from Cancer Research UK and the Medical Research Council.

On the primary outcome, the patches held. Metastasis-free survival at three years was 87.1% in the patch group and 85.9% in the injection group, meeting the trial's criterion for noninferiority. Five-year overall survival was 81.1% with patches and 79.2% with injections. Serious adverse events of grade 3 or higher occurred in 16% of the patch group and 19% of the injection group.

The symptom data is where this trial becomes relevant to anyone thinking about menopause. Hot flashes of any severity affected 44% of the men on patches compared with 89% of men on injections. Moderate to severe hot flashes affected 8% versus 37%. Breast tissue growth went the other way, affecting 85% of the patch group against 42% on injections, which is the expected trade-off when estrogen is added back rather than removed.

Read that hot flash comparison again. Steady estradiol through the skin reduced hot flashes by more than half, in a randomized setting, with fifteen years of follow-up behind it. That level of evidence does not exist for the 40 million or so women in the United States living with menopause symptoms right now.

Why swallowing estrogen is not the same as absorbing it

The reason a patch and a tablet behave differently has nothing to do with the hormone. Estradiol is estradiol. What differs is where it lands first.

Swallow a tablet and it travels from the gut to the liver before it reaches general circulation. This is called first-pass metabolism, and the liver responds to that concentrated arrival by adjusting output of several proteins, including clotting factors and inflammatory markers. Deliver the same molecule through a skin patch and it enters the bloodstream directly. The liver sees ordinary circulating levels rather than a bolus, and the clotting response largely does not occur.

That distinction was quantified in a 2019 analysis published in the BMJ by Yana Vinogradova and colleagues, drawing on UK primary care records. The researchers compared 80,396 women aged 40 to 79 who had been diagnosed with venous thromboembolism against 391,494 matched controls. Oral hormone therapy carried roughly 70% higher clot risk than transdermal. Transdermal preparations showed no association with clot risk at all, with an adjusted odds ratio of 0.93 and a confidence interval of 0.87 to 1.01. The authors noted that transdermal treatment appears underused, and that oral preparations remain the overwhelming preference.

Delivery route What happens in the body Effect on clot risk
Oral tablet Absorbed through the gut, concentrated in the liver before general circulation Liver increases clotting factor output, raising risk
Transdermal patch Absorbed through skin into the bloodstream, bypassing first-pass liver metabolism No measurable increase in the BMJ analysis
Transdermal gel or spray Same skin absorption pathway, with dosing that varies more between applications Grouped with patches in most analyses, with less dedicated data
Vaginal estrogen Acts locally on urogenital tissue with minimal systemic absorption Not associated with systemic clot risk

 

Pro Tip: If a clinician cites clot risk as the reason to avoid hormone therapy, it is worth asking whether that figure refers to oral or transdermal preparations. Much of the risk language still in circulation traces back to trials that used oral conjugated equine estrogens, a different drug delivered by a different route.

The estrogen patch questions that still have no randomized answer

Observational data is useful, and the BMJ analysis is large and well conducted. It is still not a randomized trial. Here is what women are asking that no adequately powered randomized trial has settled.

Does a patch protect the heart? The Kronos Early Estrogen Prevention Study, known as KEEPS, randomized 727 recently postmenopausal women to oral conjugated estrogens, transdermal estradiol, or placebo for four years. Its primary measure was carotid artery wall thickness, a surrogate marker rather than an actual cardiac event. Neither treatment changed the rate at which that thickness increased. The study was never designed or sized to detect heart attacks or strokes.

Does it change stroke risk? Oral estrogen has been associated with elevated stroke risk in older trials. Whether the transdermal route removes that signal has not been tested in a randomized trial with stroke as an endpoint.

Does it affect dementia risk? The KEEPS Continuation Study followed participants for roughly ten years after the original four-year treatment period and published in PLOS Medicine in November 2024. Cognitive performance in women who had received transdermal estradiol did not differ from placebo. That finding is informative, and it comes from a study of 727 women whose treatment lasted four years, which is a narrow window from which to draw conclusions about a disease that develops across decades.

What about women with elevated clot risk? Women with a personal or family history of clotting are the group most likely to benefit if the transdermal route truly avoids the liver effect. They are also the group most often excluded from trials, so the question has never been tested directly in the population that needs the answer.

The funding picture explains part of this. A congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine found that 8.8% of NIH grant spending from 2013 to 2023 went to women's health research, and that this share has fallen as a proportion of the overall NIH budget even while the agency's budget grew. The report also noted that menopause sits outside the primary remit of all 27 existing NIH institutes and centers. Menopause did not appear as its own tracked NIH funding category until 2024.

How patches, pills, and non-hormonal approaches compare

None of this makes the patch right for everyone, and none of it makes tablets wrong. Both are legitimate options, and the decision belongs with a woman and her clinician working from her own history. What follows is a summary of where each approach currently stands.

Approach Strengths Considerations Best suited to
Transdermal estradiol patch Steady hormone levels, no first-pass liver effect, strongest safety signal on clot risk Skin irritation, adhesion problems in heat, intermittent supply shortages Women with clotting concerns, migraine with aura, or high triglycerides
Oral estradiol tablet Simple to take, widely stocked, generally lower cost Higher clot risk than transdermal in large observational data Women at low baseline clot risk who prefer a daily tablet
Vaginal estrogen Targets dryness, urinary symptoms, and discomfort with minimal systemic exposure Does not address hot flashes, sleep, or mood Women whose main symptoms are urogenital
Non-hormonal prescription options Avoids estrogen entirely, useful after hormone-sensitive cancers Side effect profiles vary widely between drug classes Women for whom estrogen is contraindicated
Botanical and nutrient support Accessible without a prescription, addresses several symptom areas at once Effect sizes are smaller than hormone therapy and vary between individuals Women waiting on a prescription, declining hormones, or wanting added support alongside them

Combining approaches is common and reasonable. Vaginal estrogen alongside a systemic patch is a standard pairing when urogenital symptoms persist. Botanical support alongside prescribed hormone therapy is also routine, though anyone doing so should tell their prescriber, since some botanicals interact with medications. Supply is a separate practical factor: patch shortages have disrupted treatment repeatedly, and a woman stabilized on one formulation might find herself switched through no clinical decision of her own.

Know when to seek professional evaluation:

  • Any leg swelling, calf pain, chest pain, or sudden shortness of breath while on hormone therapy
  • Vaginal bleeding after menopause, or a change in bleeding pattern on hormone therapy
  • A personal or family history of blood clots, stroke, or hormone-sensitive cancer before starting treatment
  • New or worsening migraine with visual aura
  • Symptoms that persist after three months on a stable dose
  • A breast lump, or any new breast change

Where Botavive Balance fits if hormone therapy is not on the table

Plenty of women are not taking hormone therapy. Some have a contraindication. Some were told no by a clinician working from outdated risk figures. Some are waiting out a supply shortage, and some have simply decided against it. The symptoms do not pause while any of that gets resolved.

Botavive Balance was formulated for that gap. It combines Dong Quai, Red Clover, Black Cohosh, and Ashwagandha with DHA, B vitamins, magnesium, and probiotics. Red Clover and Black Cohosh have the longest research history in the hot flash and night sweat literature, which is the symptom cluster the prostate cancer trial measured so precisely. Ashwagandha addresses the stress response that tends to amplify those symptoms, and the probiotic component supports the gut bacteria involved in estrogen metabolism.

Balance is nutritional support, not a substitute for prescribed hormone therapy, and it is not positioned as one. Effect sizes for botanicals are smaller than for estradiol. For women who are not on hormone therapy, or who want additional support alongside it, it is one part of a broader plan that also includes sleep, strength training, and protein intake. Anyone taking prescription medication or managing a hormone-sensitive condition should review the ingredient list with their clinician first.

Frequently asked questions

Does a prostate cancer trial tell us anything about menopause?

Partly. The hormonal state is comparable, because both involve suppressed sex hormones producing hot flashes, joint pain, and cognitive complaints. What transfers well is the pharmacology, meaning how steadily the patch delivers estradiol and how the body responds to that steady level. What does not transfer is anything specific to female physiology, including breast tissue, the uterus, and bone density in women. The trial is a strong signal, not a substitute.

Why is the patch prescribed less often than tablets if it looks safer?

Prescribing habits formed decades ago around oral preparations and have been slow to shift. Cost, formulary rules, and patient familiarity with tablets all play a part. The BMJ authors made this point directly, describing transdermal treatment as underused despite the safety data.

How long does an estrogen patch take to work?

Most women notice a change in hot flashes and night sweats within two to four weeks, with fuller benefit by around three months. Sleep and mood often improve earlier than skin, hair, and joint symptoms, which respond over a longer period.

If the research is this thin, is hormone therapy safe?

The gap described here is about specific unanswered questions, not about a lack of evidence overall. Hormone therapy is among the better-studied treatments in medicine for symptom relief. What is missing is randomized evidence on long-term outcomes such as heart disease, stroke, and dementia risk specifically for the transdermal route in women. That distinction matters when weighing a decision, and it is worth discussing with a clinician who works in menopause care.

Is it worth asking to switch from a tablet to a patch?

That depends on individual risk factors, particularly any history of clotting, migraine with aura, or elevated triglycerides, which are the situations where the transdermal route has the clearest advantage. It is a reasonable conversation to open with a prescriber rather than a change to make independently.

Sources

  1. Langley RE, Gilbert DC, Mangar S, et al., 2026. Transdermal estradiol patches were noninferior to LHRH agonists for three-year metastasis-free survival in 1,360 men with locally advanced prostate cancer, with hot flashes in 44% versus 89%. New England Journal of Medicine. pubmed.ncbi.nlm.nih.gov/41880608
  2. Vinogradova Y, Coupland C, Hippisley-Cox J, 2019. Oral hormone therapy carried roughly 70% higher venous thromboembolism risk than transdermal across 80,396 cases and 391,494 controls, with transdermal showing no increased risk. BMJ. pubmed.ncbi.nlm.nih.gov/30626577
  3. National Academies of Sciences, Engineering, and Medicine, 2024. Only 8.8% of NIH grant spending from 2013 to 2023 focused on women's health research, and menopause falls outside the remit of all 27 existing NIH institutes and centers. nationalacademies.org
  4. Gleason CE, Dowling NM, Kara F, et al., 2024. Ten years after four years of treatment, cognitive performance in women randomized to transdermal estradiol did not differ from placebo in the KEEPS Continuation Study. PLOS Medicine. pmc.ncbi.nlm.nih.gov/articles/PMC11581397

Related articles

Previous post Next post
Back to blog